Table 3. Patients' characteristics.
| No | Study | Age; median years (range); HSCT vs. IST | Gender; N. males ∶ N. females (% males); HSCT vs. IST | Time interval from diagnosis to treatment; median days (range); HSCT vs. IST |
| 1 | Ahn 2003 [31] | (14–≥41) vs. (14–≥41) | 33 ∶ 31 (57) vs. 72 ∶ 84 (46) | – |
| 2 | Arranz 1994 [32] | 24 (12–46) vs. 38 (8–71) | – | 50 (8–1145) vs. 60 (2–1889) |
| 3 | Bacigalupo 1988 [33] | (0–50) vs. (0–50) | 135 ∶ 82 (62) vs. 162 ∶ 126 (56) | (0–>90) vs. (0–>90) |
| 4 | Bacigalupo 2000 [34] | – | – | 90 vs. 35 |
| 5 | Bayever 1984 [35] | 17 (2–24) vs. 15 (1–23) | 23 ∶ 12 (66) vs. 15 ∶ 7 (68) | 60 (9–2520) vs. 58 (8–2669) |
| 6 | Champlin 1984 [36] | 17 (1–44) vs. 31 (1–76) | 43 ∶ 18 (71) vs. 41 ∶ 28 (59) | 60 (7–1440) vs. 64 (3–2671) |
| 7 | De Planque 1990 [37] | 27 (13–85) across groups | 42 ∶ 40 across groups | – |
| 8 | Doney 1997 [38] | 22 (2–53) vs. 25 (1–74) | 101 ∶ 67 (60) vs. 102 ∶ 125 (45) | 30 (6–6822) vs. 42 (3–4590) |
| 9 | Fouladi 2000 [39] | 9 (2–16) vs. 10 (1–17) | 16 ∶ 5 (76) vs. 11 ∶ 9 (55) | 54 (18–165) vs. 12 (0–60) |
| 10 | Führer 1998 [40] | 10 (2–16) vs. 9 (1–15) | 12 ∶ 16 (43) vs. 53 ∶ 33 (62) | 49 (18–272) vs. 23 (3–168) |
| 11 | Führer 2005 [41] | 9 (1–17) across groups | 125 ∶ 88 across groups | 27 (1–268) across groups |
| 12 | Ghavamzadeh 2004 [42] | 19 vs. 25 mean | 19 ∶ 10 (63) vs. 18 ∶ 6 (75) | – |
| 13 | Gillio 1997 [43] | 12 (2–19) vs. 14 (1–20) | 14 ∶ 11 (56) vs. 18 ∶ 5 (78) | 27 (5–2124) vs. 35 (10–4383) |
| 14 | Gluckman 1979 [44] | 19 (3–31) vs. 21 (4–56) | 23 ∶ 14 (62) vs. 15 ∶ 13 (54) | 90 (8–2520) vs. 120 (15–1152) |
| 15 | Halperin 1989 [45] | 8 (1–18) across groups | 21 ∶ 15 across groups | 27 (15–120) vs. 30 (6–180) |
| 16 | Kahn 2002 [46] | 22 (6–59) vs. 55 (9–78) | 8 ∶ 7 (53) vs. 10 ∶ 6 (63) | 38 (14–866) vs. 12 (2–183) |
| 17 | Kim 2003 [47] | 22 (14–43) vs. 34 (15–75) | 16 ∶ 6 (73) vs. 37 ∶ 37 (50) | 300 (30–3540) vs. 150 (30–10920) |
| 18 | Kojima 2000 [48] | 10 (0–16) vs. 9 (1–17) | 18 ∶ 19 (49) vs. 31 ∶ 32 (49) | 38 (20–2040) vs. 24 (12–2490) |
| 19 | Lawlor 1997 [49] | 13 (4–17) vs. 7 (2–14) | 4 ∶ 5 (44) vs. 9 ∶ 9 (50) | – |
| 20 | Locasciulli 1990 [50] | (0–15) vs. (0–15) | 97 ∶ 74 (57) vs. 71 ∶ 62 (53) | (0–>90) vs. (0–>90) |
| 21 | Locasciulli 2007 [51] | 19 (1–67) vs. 24 (1–94) | 959 ∶ 605 (61) vs. 520 ∶ 390 (57) | 81 (1–3661) vs. 23 (1–1375) |
| 22 | Paquette 1995 [52] | (16–>30) vs. (16–>30) | – | – |
| 23 | Pitcher 1999 [53] | (1–14) across groups | 40 ∶ 35 across groups | – |
| 24 | Tzeng 1989 [54] | 20 (10–35) vs. 27 (19–56) | 5 ∶ 4 (56) vs. 3 ∶ 4 (43) | – |
| 25 | Viollier 2005 [55] | 19 (2–55) vs. 23 (2–74) | 27 ∶ 25 (52) vs. 85 ∶ 70 (55) | 51 (6–420) vs. 36 (1–11340) |
| 26 | Werner 1989 [56] | (3–15) vs. (1–16) | 4 ∶ 2 (67) vs. 5 ∶ 4 (56) | (7–56) vs. (7–406) |
–: information not extractable from publication.
Abbreviations: HSCT: hematopoietic stem cell transplantation; IST: immunosuppressive therapy.